Articles

FDA Approves Gilead's Hepatitis D Drug: Implications for Pharma

The FDA has cleared Gilead's hepatitis D drug after a four-year wait, marking a significant milestone in hepatitis treatment. This article explores the implications for the pharmaceutical landscape.

AbbVie and GSK Surge in UK Patient Reputation Rankings

AbbVie and GSK have made significant strides in patient reputation rankings in the UK. This article explores the implications for the pharmaceutical sector.

ASCO26: Key Data Insights Ahead of the Major Cancer Drug Meeting

As ASCO26 approaches, we delve into five critical data snapshots that will shape the future of cancer drug development. This article provides insights for pharma teams and investors.

Novartis and AbbVie Layoffs: Implications for the Pharma Industry

Novartis and AbbVie are planning significant layoffs this summer. This article examines the implications for the pharmaceutical industry and business teams.

FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection

The FDA has approved the first treatment for Chronic Hepatitis Delta Virus (HDV) infection, marking a significant milestone in liver disease management. This article explores the implications for pharmaceutical companies and investors.

Five Key Regulatory Updates to Watch at ASCO

This article highlights five crucial regulatory updates at ASCO, particularly focusing on Daraxonrasib and its potential impact on the pharmaceutical landscape.

Get Ready for RESI San Diego 2026: Key Insights and What to Expect

The RESI San Diego 2026 event is set to be a pivotal gathering for B2B stakeholders in the pharma industry. Here's what you need to know ahead of the event.

Biogen and Denali Abandon Parkinson's Drug After Study Setback

Biogen and Denali have decided to discontinue their drug for non-genetic Parkinson's disease following disappointing mid-stage study results. This article explores the implications for the pharmaceutical landscape.

The Future of Men's Health: A Federal Office on the Horizon

As discussions around a federal office of men's health gain momentum, the pharmaceutical industry must prepare for potential shifts in focus and investment. This article delves into the implications for pharma teams.

Harnessing AI for Efficient Doctor's Office Check-Ins

This article discusses the potential of AI to revolutionize check-in and intake processes in healthcare, focusing on its implications for pharmaceutical companies.

EU and US Split on AstraZeneca's Breast Cancer Drug Approval

AstraZeneca's breast cancer drug faces differing opinions from EU and US regulators. This article explores the implications for pharma stakeholders.

The Seed Oil Panic: Implications for Cardiac Health

This article discusses how the growing panic around seed oils is negatively affecting cardiac patients and the pharmaceutical industry's response.

Latest Insights on Parkinson’s Drug Setback and Merck’s Lung Cancer Therapy

This article reviews recent developments in Parkinson’s drug trials and Merck’s lung cancer therapy, highlighting their implications for the pharmaceutical industry.

Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss

This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.

Why One Health AI Unicorn is Offering Free Services

A leading health AI unicorn has decided to offer its services for free, raising questions about its strategy and implications for the pharma sector. This article explores the motivations and potential impacts of this decision.

CDC's Mpox Page: Caught in Political Crosshairs

The CDC's mpox page faces scrutiny amid political tensions, raising questions for pharmaceutical stakeholders.

Genentech's Strategy to Influence Pharma Reforms

Genentech is actively soliciting research to mitigate the impact of proposed pharmaceutical reforms in Washington. This article explores the implications for the industry.

Ibrance Heirs and Gilead's Tubulis Data at ASCO26

This article delves into the latest developments from ASCO26, focusing on Ibrance heirs and Gilead's Tubulis data. Discover the implications for pharmaceutical stakeholders.

#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck

Kelun's Phase 3 study on lung cancer in partnership with Merck showcased significant success at ASCO26. This article explores the implications for the pharma industry.

Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%

Merck-Kelun's recent trial results indicate a significant breakthrough in lung cancer treatment, with a 65% reduction in tumor progression risk. This article explores the implications for the pharmaceutical industry.